Base de dados : MEDLINE
Pesquisa : D03.383.742.175 [Categoria DeCS]
Referências encontradas : 7328 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 733 ir para página                         

  1 / 7328 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29181841
[Au] Autor:Ray A; Ray S
[Ad] Endereço:Department of Obstetrics and Gynaecology, DM Wayanad Institute of Medical Sciences, Naseera Nagar ,Meppadi (PO), Wayanad, Wayanad, Kerala, India, 673577.
[Ti] Título:Epidural therapy for the treatment of severe pre-eclampsia in non labouring women.
[So] Source:Cochrane Database Syst Rev;11:CD009540, 2017 11 28.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Pre-eclampsia is a pregnancy-specific multi-organ disorder, which is characterised by hypertension and multisystem organ involvement and which has significant maternal and fetal morbidity and mortality. Failure of the placental vascular remodelling and reduced uteroplacental flow form the etiopathological basis of pre-eclampsia. There are several established therapies for pre-eclampsia including antihypertensives and anticonvulsants. Most of these therapies aim at controlling the blood pressure or preventing complications of elevated blood pressure, or both. Epidural therapy aims at blocking the vasomotor tone of the arteries, thereby increasing uteroplacental blood flow. This review was aimed at evaluating the available evidence about the possible benefits and risks of epidural therapy in the management of severe pre-eclampsia, to define the current evidence level of this therapy, and to determine what (if any) further evidence is required. OBJECTIVES: To assess the effectiveness, safety and cost of the extended use of epidural therapy for treating severe pre-eclampsia in non-labouring women. This review aims to compare the use of extended epidural therapy with other methods, which include intravenous magnesium sulphate, anticonvulsants other than magnesium sulphate, with or without use of the antihypertensive drugs and adjuncts in the treatment of severe pre-eclampsia.This review only considered the use of epidural anaesthesia in the management of severe pre-eclampsia in the antepartum period and not as pain relief in labour. SEARCH METHODS: We searched Cochrane Pregnancy and Childbirth's Trials Register, ClinicalTrials.gov and the WHO International Clinical Trials Registry Platform (ICTRP) (13 July 2017) and reference lists of retrieved studies. SELECTION CRITERIA: Randomised controlled trials (RCTs) or quasi-RCTs comparing epidural therapy versus traditional therapy for pre-eclampsia in the form of antihypertensives, anticonvulsants, magnesium sulphate, low-dose dopamine, corticosteroids or a combination of these, were eligible for inclusion. Trials using a cluster design, and studies published in abstract form only are also eligible for inclusion in this review. Cross-over trials were not eligible for inclusion in this review. DATA COLLECTION AND ANALYSIS: The two review authors independently assessed trials for inclusion and trial quality. There were no relevant data available for extraction. MAIN RESULTS: We included one small study (involving 24 women). The study was a single-centre randomised trial conducted in Mexico. This study compared a control group who received antihypertensive therapy, anticonvulsant therapy, plasma expanders, corticosteroids and dypyridamole with an intervention group that received epidural block instead of the antihypertensives, as well as all the other four drugs. Lumbar epidural block was given using 0.25% bupivacaine, 10 mg bolus and 5 mg each hour on continuous epidural infusion for six hours. This study was at low risk of bias in three domains but was assessed to be high risk of bias in two domains due to lack of allocation concealment and blinding of women and staff, and unclear for random sequence generation and outcome assessor blinding.The included study did not report on any of this review's important outcomes. Meta-analysis was not possible.For the mother, these were: maternal death (death during pregnancy or up to 42 days after the end of the pregnancy, or death more than 42 days after the end of the pregnancy); development of eclampsia or recurrence of seizures; stroke; any serious morbidity: defined as at least one of stroke, kidney failure, liver failure, HELLP syndrome (haemolysis, elevated liver enzymes and low platelets), disseminated intravascular coagulation, pulmonary oedema.For the baby, these were: death: stillbirths (death in utero at or after 20 weeks' gestation), perinatal deaths (stillbirths plus deaths in the first week of life), death before discharge from the hospital, neonatal deaths (death within the first 28 days after birth), deaths after the first 28 days; preterm birth (defined as the birth before 37 completed weeks' gestation); and side effects of the intervention. Reported outcomesThe included study only reported on a single secondary outcome of interest to this review: the Apgar score of the baby at birth and after five minutes and there was no clear difference between the intervention and control groups.The included study also reported a reduction in maternal diastolic arterial pressure. However, the change in maternal mean arterial pressure and systolic arterial pressure, which were the other reported outcomes of this trial, were not significantly different between the two groups. AUTHORS' CONCLUSIONS: Currently, there is insufficient evidence from randomised controlled trials to evaluate the effectiveness, safety or cost of using epidural therapy for treating severe pre-eclampsia in non-labouring women.High-quality randomised controlled trials are needed to evaluate the use of epidural agents as therapy for treatment of severe pre-eclampsia. The rationale for the use of epidural is well-founded. However there is insufficient evidence from randomised controlled trials to show that the effect of epidural translates into improved maternal and fetal outcomes. Thus, there is a need for larger, well-designed studies to come to an evidence-based conclusion as to whether the lowering of vasomotor tone by epidural therapy results in better maternal and fetal outcomes and for how long that could be maintained. Another important question that needs to be answered is how long should extended epidural be used to ensure any potential clinical benefits and what could be the associated side effects and costs. Interactions with other modalities of treatment and women's satisfaction could represent other avenues of research.
[Mh] Termos MeSH primário: Anestesia Epidural/métodos
Anestesia Obstétrica/métodos
Anestésicos Locais/administração & dosagem
Bupivacaína/administração & dosagem
Pré-Eclâmpsia/terapia
[Mh] Termos MeSH secundário: Corticosteroides/uso terapêutico
Anticonvulsivantes/uso terapêutico
Anti-Hipertensivos/uso terapêutico
Dipiridamol/uso terapêutico
Feminino
Seres Humanos
Substitutos do Plasma/uso terapêutico
Gravidez
Vasodilatadores/uso terapêutico
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, NON-U.S. GOV'T; REVIEW
[Nm] Nome de substância:
0 (Adrenal Cortex Hormones); 0 (Anesthetics, Local); 0 (Anticonvulsants); 0 (Antihypertensive Agents); 0 (Plasma Substitutes); 0 (Vasodilator Agents); 64ALC7F90C (Dipyridamole); Y8335394RO (Bupivacaine)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180116
[Lr] Data última revisão:
180116
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD009540.pub2


  2 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28956647
[Au] Autor:Chen K; Wen H; Yang F; Yu Y; Gai X; Wang H; Li P; Pan W; Yang X
[Ad] Endereço:a Department of Pharmaceutics , School of Pharmaceutical Sciences, Shenyang Pharmaceutical University , Shenyang , China.
[Ti] Título:Study of controlled-release floating tablets of dipyridamole using the dry-coated method.
[So] Source:Drug Dev Ind Pharm;44(1):116-124, 2018 Jan.
[Is] ISSN:1520-5762
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:Dipyridamole (DIP), having a short biological half-life, has a narrow absorption window and is primarily absorbed in the stomach. So, the purpose of this study was to prepare controlled-release floating (CRF) tablets of dipyridamole by the dry-coated method. The influence of agents with different viscosity, hydroxypropylmethylcellulose (HPMC) and polyvinylpyrollidon K30 (PVP K30) in the core tablet and low-viscosity HPMC and PVP K30 in the coating layer on drug release, were investigated. Then, a study with a three-factor, three-level orthogonal experimental design was used to optimize the formulation of the CRF tablets. After data processing, the optimized formulation was found to be: 80 mg HPMC K4M in the core tablet, 80 mg HPMC E15 in core tablet and 40 mg PVP K30 in the coating layer. Moreover, an in vitro buoyancy study showed that the optimized formulation had an excellent floating ability and could immediately float without a lag time and this lasted more than 12 h. Furthermore, an in vivo gamma scintigraphic study showed that the gastric residence time of the CRF tablet was about 8 h.
[Mh] Termos MeSH primário: Química Farmacêutica/métodos
Dipiridamol/química
Excipientes/química
Derivados da Hipromelose/química
Povidona/análogos & derivados
Povidona/química
Comprimidos/química
[Mh] Termos MeSH secundário: Preparações de Ação Retardada
Dipiridamol/farmacocinética
Meia-Vida
Comprimidos/farmacocinética
Viscosidade
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Delayed-Action Preparations); 0 (Excipients); 0 (Tablets); 0 (polyvinylpyrollidon K30); 3NXW29V3WO (Hypromellose Derivatives); 64ALC7F90C (Dipyridamole); FZ989GH94E (Povidone)
[Em] Mês de entrada:1801
[Cu] Atualização por classe:180111
[Lr] Data última revisão:
180111
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170929
[St] Status:MEDLINE
[do] DOI:10.1080/03639045.2017.1386198


  3 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28942444
[Au] Autor:Flintholm Raft K; Frestad D; Michelsen MM; Suhrs HE; Rask AB; Nilsson M; Hermann TS; Prescott E
[Ad] Endereço:Department of Cardiology, Bispebjerg University Hospital, Copenhagen, Denmark.
[Ti] Título:Peripheral Endothelial Function and Coronary Flow Velocity Reserve Are Not Associated in Women with Angina and No Obstructive Coronary Artery Disease: The iPOWER Study.
[So] Source:J Vasc Res;54(5):309-319, 2017.
[Is] ISSN:1423-0135
[Cp] País de publicação:Switzerland
[La] Idioma:eng
[Ab] Resumo:PURPOSE: We investigated whether impaired flow-mediated dilation (FMD) and plasma biomarkers reflecting endothelial dysfunction are associated with coronary microvascular dysfunction (CMD) in women with angina and no obstructive coronary artery disease (CAD). METHODS: Patients (n = 194) were randomly selected women with angina pectoris and no obstructive CAD (<50% stenosis). A reference population of asymptomatic women without CAD (n = 25) was included. We measured FMD in the brachial artery by high-resolution ultrasound. Coronary flow velocity reserve (CFVR) was assessed by transthoracic Doppler flow echocardiography (TTDE) of the left anterior descending artery during rest and high-dose dipyridamole infusion. CMD was defined as CFVR <2. RESULTS: FMD and CFVR were measured in 128 patients and 21 controls. Mean (SD) age was 64.5 (8.9) years, mean CFVR was 2.3 (2.0-2.7), and mean FMD was 8.4% (4.8%) in angina patients. Angina patients had a higher risk factor burden compared with the reference population. Measures of peripheral endothelial dysfunction and endothelial plasma biomarkers did not differ according to angina or CFVR. CFVR and FMD did not correlate (Spearman ρ = -0.07, p = 0.45). CONCLUSIONS: FMD and biomarkers of endothelial dysfunction did not identify individuals with CMD assessed as impaired CFVR by TTDE in women with angina and no obstructive CAD.
[Mh] Termos MeSH primário: Angina Pectoris/fisiopatologia
Artéria Braquial/fisiopatologia
Estenose Coronária/fisiopatologia
Vasos Coronários/fisiopatologia
Endotélio Vascular/fisiopatologia
Reserva Fracionada de Fluxo Miocárdico
Vasodilatação
[Mh] Termos MeSH secundário: Idoso
Angina Pectoris/diagnóstico
Angina Pectoris/etiologia
Velocidade do Fluxo Sanguíneo
Artéria Braquial/diagnóstico por imagem
Estenose Coronária/complicações
Estenose Coronária/diagnóstico por imagem
Dipiridamol/administração & dosagem
Ecocardiografia Doppler
Feminino
Seres Humanos
Microcirculação
Meia-Idade
Valor Preditivo dos Testes
Fluxo Sanguíneo Regional
Fatores de Risco
Índice de Gravidade de Doença
Vasodilatadores/administração & dosagem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Vasodilator Agents); 64ALC7F90C (Dipyridamole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171023
[Lr] Data última revisão:
171023
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170925
[St] Status:MEDLINE
[do] DOI:10.1159/000479374


  4 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo SciELO Brasil
[PMID]:28902285
[Au] Autor:Santeliz S; Caicedo P; Giraldo E; Alvarez C; Yustiz MD; Rodríguez-Bonfante C; Bonfante-Rodríguez R; Bonfante-Cabarcas R
[Ad] Endereço:Decanato de Ciencias Veterinarias, Unidad de Biomedicina, Departamento de Medicina y Cirugía, Barquisimeto, Estado Lara, Venezuela.
[Ti] Título:Dipyridamole potentiated the trypanocidal effect of nifurtimox and improved the cardiac function in NMRI mice with acute chagasic myocarditis.
[So] Source:Mem Inst Oswaldo Cruz;112(9):596-608, 2017 Sep.
[Is] ISSN:1678-8060
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: As chronic Chagas disease does not have a definitive treatment, the development of alternative therapeutic protocols is a priority. Dipyridamole (DPY) is an alternative to counteract the pathophysiological phenomena involved in Chagas cardiomyopathy. OBJECTIVE: To evaluate the therapeutic efficacy of DPY associated with nifurtimox (Nfx) in epimastigote axenic cultures and in mice with acute Chagas disease. METHODS: NMRI adult male mice were divided into nine groups: three healthy and six Trypanosoma cruzi-infected groups. Mice received vehicle, Nfx or DPY, alone or combined. The doses assayed were Nfx 10 and 40 mg/kg and DPY 30 mg/kg. The treatment efficacy was evaluated by clinical, electrocardiographic, parasitological, biochemical and histopathological methods. FINDINGS: In vitro, DPY and Nfx had a trypanocidal effect with IC50 values of 372 ± 52 and 21.53 ± 2.13 µM, respectively; DPY potentiated the Nfx effect. In vivo, Nfx (40 mg/kg) with or without DPY had a therapeutic effect, which was reflected in the 84-92% survival rate and elimination of parasitaemia and heart tissue amastigotes. Nfx (10 mg/kg) had a subtherapeutic effect with no survival and persistence of amastigotes, inflammation and fibrosis in heart tissue; adding DPY increased the survival rate to 85%, and all tested parameters were significantly improved. MAIN CONCLUSION: DPY has a trypanocidal effect in vitro and enhances the Nfx therapeutic effect in an in vivo murine model.
[Mh] Termos MeSH primário: Cardiomiopatia Chagásica/tratamento farmacológico
Dipiridamol/uso terapêutico
Nifurtimox/uso terapêutico
Tripanossomicidas/uso terapêutico
[Mh] Termos MeSH secundário: Doença Aguda
Animais
Modelos Animais de Doenças
Sinergismo Farmacológico
Quimioterapia Combinada
Masculino
Camundongos
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Trypanocidal Agents); 64ALC7F90C (Dipyridamole); M84I3K7C2O (Nifurtimox)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171109
[Lr] Data última revisão:
171109
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170914
[St] Status:MEDLINE


  5 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28727374
[Au] Autor:Kutlu O; Karaguzel E; Okatan AE; Mentese A; Yulug E; Kazaz IO; Kutlu S; Dil E; Eren H; Alver A
[Ad] Endereço:Department of Urology, School of Medicine, Akdeniz University, Antalya, Turkey.
[Ti] Título:Dipyridamole reduces penile apoptosis in a rat model of post-prostatectomy erectile dysfunction.
[So] Source:Int Braz J Urol;43(5):966-973, 2017 Sep-Oct.
[Is] ISSN:1677-6119
[Cp] País de publicação:Brazil
[La] Idioma:eng
[Ab] Resumo:PURPOSE: Despite the nerve-sparing technique, many patients suffer from erectile dysfunction after radical prostatectomy (RP) due to cavernous nerve injury. The aim of this study was to evaluate dipyridamole as a potential treatment agent of post-radical prostatectomy erectile dysfunction. MATERIAL AND METHODS: A total of 18 male Sprague-Dawley rats were randomized into three experimental Groups (SHAM+DMSO, BCNI+DMSO and BCNI+DIP). An animal model of bilateral cavernous nerve crush injury (BCNI) was established to mimic the partial nerve damage during nerve-sparing RP. After creating of BCNI, dimethyl sulphoxide (DMSO) was administered transperitoneally as a vehicle to SHAM+DMSO and BCNI+DMSO Groups. BCNI+DIP Group received dipyiridamole (10mg/kg/day) as a solution in DMSO for 15 days. Afterwards, rats were evaluated for in vivo erectile response to cavernous nerve stimulation. Penile tissues were also analyzed biochemically for transforming growth factor-ß1 (TGF-ß1) level. Penile corporal apoptosis was determined by TUNEL method. RESULTS: Erectile response was decreased in rats with BCNI and there was no significant improvement with dipyridamole treatment. TGF-ß1 levels were increased in rats with BCNI and decreased with dipyridamole treatment. Dipyridamole led to reduced penile apoptosis in rats with BCNI and there was no significant difference when compared to sham operated rats. CONCLUSIONS: Although fifteen-day dipyridamole treatment has failed to improve erectile function in rats with BCNI, the decline in both TGF-ß1 levels and apoptotic indices with treatment may be helpful in protecting penile morphology after cavernous nerve injury.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Dipiridamol/uso terapêutico
Disfunção Erétil/tratamento farmacológico
Prostatectomia/efeitos adversos
[Mh] Termos MeSH secundário: Animais
Modelos Animais de Doenças
Disfunção Erétil/etiologia
Masculino
Pênis/efeitos dos fármacos
Distribuição Aleatória
Ratos
Ratos Sprague-Dawley
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
64ALC7F90C (Dipyridamole)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171117
[Lr] Data última revisão:
171117
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170721
[St] Status:MEDLINE
[do] DOI:10.1590/S1677-5538.IBJU.2017.0023


  6 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
[PMID]:28719377
[Au] Autor:Ferreira AO; Polonini H; da Silva SL; Aglio NCB; Abreu J; Fernandes BMA
[Ad] Endereço:Ortofarma - Quality Control Laboratories, Matias Barbosa, MG, Brazil.
[Ti] Título:Stability of Acetazolamide, Baclofen, Dipyridamole, Mebeverine Hydrochloride, Propylthiouracil, Quinidine Sulfate, and Topiramate Oral Suspensions in SyrSpend SF PH4.
[So] Source:Int J Pharm Compd;21(4):339-346, 2017 Jul-Aug.
[Is] ISSN:1092-4221
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:The objective of this study was to evaluate the stability of 7 commonly used active pharmaceutical ingredients compounded in oral suspensions using an internationally used suspending vehicle (SyrSpend SF PH4): acetazolamide 25.0 mg/mL, baclofen 10.0 mg/mL, dipyridamole 10.0 mg/mL, mebeverine hydrochloride 10.0 mg/mL, propylthiouracil 5.0 mg/mL, quinidine sulfate 10.0 mg/mL, and topiramate 5.0 mg/mL. All suspensions were stored both at controlled refrigerated (2°C to 8°C) and room temperature (20°C to 25°C). Stability was assessed by measuring the percentage recovery at varying time points throughout a 90-day period. Active pharmaceutical ingredient quantification was performed by ultraviolet (UV) high-performance liquid chromatography, via a stability-indicating method. Given the percentage of recovery of the active pharmaceutical ingredients within the suspensions, the beyond-use date of the final products (active pharmaceutical ingredient + vehicle) was at least 90 days for all suspensions with regards to both temperatures. This suggests that SyrSpend SF PH4 is suitable for compounding active pharmaceutical ingredients from different pharmacological classes.
[Mh] Termos MeSH primário: Composição de Medicamentos
Estabilidade de Medicamentos
[Mh] Termos MeSH secundário: Acetazolamida/química
Administração Oral
Baclofeno/química
Cromatografia Líquida de Alta Pressão
Dipiridamol/química
Frutose/análogos & derivados
Frutose/química
Fenetilaminas/química
Propiltiouracila/química
Quinidina/química
Suspensões
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Phenethylamines); 0 (Suspensions); 0H73WJJ391 (topiramate); 30237-26-4 (Fructose); 64ALC7F90C (Dipyridamole); 721M9407IY (Propylthiouracil); 7F80CC3NNV (mebeverine); H789N3FKE8 (Baclofen); ITX08688JL (Quinidine); O3FX965V0I (Acetazolamide)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:170912
[Lr] Data última revisão:
170912
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170719
[St] Status:MEDLINE


  7 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28510131
[Au] Autor:Knox PP; Timofeev KN; Gorokhov VV; Seifullina NK; Rubin AB
[Ad] Endereço:Faculty of Biology, Moscow State University, Moscow, 119234, Russia.
[Ti] Título:Generation of radical form of dipyridamole at illumination of photosynthetic reaction centers of Rb. sphaeroides.
[So] Source:Dokl Biochem Biophys;473(1):118-121, 2017 Mar.
[Is] ISSN:1608-3091
[Cp] País de publicação:Russia (Federation)
[La] Idioma:eng
[Ab] Resumo:The study of the effect of vasodilator, antiplatelet agent, and inhibitor P-glycoprotein dipyridamole (DIP) on the functioning of the transmembrane protein of the reaction center (RC) of Rb. sphaeroides showed that the activation of RC by constant light generates the DIP radical cation, which significantly affects the kinetics of recombination of charges divided between photoactive bacteriochlorophyll and quinone acceptors. Thus, the antioxidant properties of DIP may affect the functional activity of membrane proteins, and this apparently should be taken into account in the studies of the mechanisms of therapeutic action of this drug.
[Mh] Termos MeSH primário: Dipiridamol/metabolismo
Luz
Complexo de Proteínas do Centro de Reação Fotossintética/metabolismo
Rhodobacter sphaeroides/metabolismo
Rhodobacter sphaeroides/efeitos da radiação
[Mh] Termos MeSH secundário: Radicais Livres/metabolismo
Cinética
Rhodobacter sphaeroides/enzimologia
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Free Radicals); 0 (Photosynthetic Reaction Center Complex Proteins); 64ALC7F90C (Dipyridamole)
[Em] Mês de entrada:1709
[Cu] Atualização por classe:171019
[Lr] Data última revisão:
171019
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170517
[St] Status:MEDLINE
[do] DOI:10.1134/S1607672917020089


  8 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28376099
[Au] Autor:Matyash M; Zabiegalov O; Wendt S; Matyash V; Kettenmann H
[Ad] Endereço:Cellular Neurosciences, Max-Delbrück Center for Molecular Medicine in the Helmholtz Association, Berlin, Germany.
[Ti] Título:The adenosine generating enzymes CD39/CD73 control microglial processes ramification in the mouse brain.
[So] Source:PLoS One;12(4):e0175012, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Microglial cells invade the brain as amoeboid precursors and acquire a highly ramified morphology in the postnatal brain. Microglia express all essential purinergic elements such as receptors, nucleoside transporters and ecto-enzymes, including CD39 (NTPDase1) and CD73 (5'-nucleotidase), which sequentially degrade extracellular ATP to adenosine. Here, we show that constitutive deletion of CD39 and CD73 or both caused an inhibition of the microglia ramified phenotype in the brain with a reduction in the length of processes, branching frequency and number of intersections with Sholl spheres. In vitro, unlike wild-type microglia, cd39-/- and cd73-/- microglial cells were less complex and did not respond to ATP with the transformation into a more ramified phenotype. In acute brain slices, wild-type microglia retracted approximately 50% of their processes within 15 min after slicing of the brain, and this phenomenon was augmented in cd39-/- mice; moreover, the elongation of microglial processes towards the source of ATP or towards a laser lesion was observed only in wild-type but not in cd39-/- microglia. An elevation of extracellular adenosine 1) by the inhibition of adenosine transport with dipyridamole, 2) by application of exogenous adenosine or 3) by degradation of endogenous ATP/ADP with apyrase enhanced spontaneous and ATP-induced ramification of cd39-/- microglia in acute brain slices and facilitated the transformation of cd39-/- and cd73-/- microglia into a ramified process-bearing phenotype in vitro. These data indicate that under normal physiological conditions, CD39 and CD73 nucleotidases together with equilibrative nucleoside transporter 1 (ENT1) control the fate of extracellular adenosine and thereby the ramification of microglial processes.
[Mh] Termos MeSH primário: 5´-Nucleotidase/metabolismo
Adenosina/metabolismo
Antígenos CD/metabolismo
Apirase/metabolismo
Encéfalo/citologia
Encéfalo/metabolismo
Microglia/citologia
Microglia/metabolismo
[Mh] Termos MeSH secundário: 5'-Nucleotidase/deficiência
5'-Nucleotidase/genética
Adenosina/farmacologia
Trifosfato de Adenosina/metabolismo
Animais
Animais Recém-Nascidos
Antígenos CD/genética
Apirase/deficiência
Apirase/genética
Encéfalo/crescimento & desenvolvimento
Lesões Encefálicas/tratamento farmacológico
Lesões Encefálicas/metabolismo
Lesões Encefálicas/patologia
Contagem de Células
Células Cultivadas
Quimiotaxia
Dipiridamol/farmacologia
Modelos Animais de Doenças
Transportador Equilibrativo 1 de Nucleosídeo/metabolismo
Redes e Vias Metabólicas
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Camundongos Transgênicos
Fenótipo
Receptores Purinérgicos P2Y12/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Antigens, CD); 0 (Equilibrative Nucleoside Transporter 1); 0 (P2ry12 protein, mouse); 0 (Receptors, Purinergic P2Y12); 0 (SLC29A1 protein, mouse); 64ALC7F90C (Dipyridamole); 8L70Q75FXE (Adenosine Triphosphate); EC 3.1.3.5 (5'-Nucleotidase); EC 3.6.1.5 (Apyrase); EC 3.6.1.5 (CD39 antigen); K72T3FS567 (Adenosine)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170828
[Lr] Data última revisão:
170828
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170405
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0175012


  9 / 7328 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28350995
[Au] Autor:Frouws MA; Rademaker E; Bastiaannet E; van Herk-Sukel MPP; Lemmens VE; Van de Velde CJH; Portielje JEA; Liefers GJ
[Ad] Endereço:Department of Surgical Oncology, Leiden University Medical Center, P.O. Box 9600, 2300 RC, The Netherlands.
[Ti] Título:The difference in association between aspirin use and other thrombocyte aggregation inhibitors and survival in patients with colorectal cancer.
[So] Source:Eur J Cancer;77:24-30, 2017 May.
[Is] ISSN:1879-0852
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: Several studies have suggested that the association between aspirin and improved cancer survival is mediated through the mechanism of aspirin as thrombocyte aggregation inhibitors (TAI). The aim of this study was to provide epidemiological evidence for this mechanism assessing the association between overall survival and the use of aspirin and non-aspirin TAI in patients with colorectal cancer. METHODS: In this observational study, data from the Netherlands Comprehensive Cancer Organisation were linked to PHARMO Database Network. Patients using aspirin or aspirin in combination with non-aspirin TAI (dual users) were selected and compared with non-users. The association between overall survival and the use of (non-)aspirin TAI was analysed using Cox regression models with the use of (non-)aspirin TAI as a time-varying covariate. RESULTS: In total, 9196 patients were identified with colorectal cancer and 1766 patients used TAI after diagnosis. Non-aspirin TAI were mostly clopidogrel and dipyridamole. Aspirin use was associated with a significant increased overall survival and hazard ratio (HR) 0.41 (95% confidence interval [CI] 0.37-0.47), and the use of non-aspirin TAI was not associated with survival of HR 0.92 (95% CI 0.70-1.22). Dual users did not have an improved overall survival when compared with patients using solely aspirin. CONCLUSIONS: Aspirin use after diagnosis of colorectal cancer was associated with significantly lower mortality rates and this effect remained significant after adjusting for potential confounders. No additional survival benefit was observed in patients using both aspirin and another TAI.
[Mh] Termos MeSH primário: Aspirina/uso terapêutico
Neoplasias Colorretais/mortalidade
Inibidores da Agregação de Plaquetas/uso terapêutico
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Dipiridamol/uso terapêutico
Quimioterapia Combinada
Feminino
Seres Humanos
Masculino
Meia-Idade
Países Baixos/epidemiologia
Análise de Sobrevida
Ticlopidina/análogos & derivados
Ticlopidina/uso terapêutico
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Platelet Aggregation Inhibitors); 64ALC7F90C (Dipyridamole); A74586SNO7 (clopidogrel); OM90ZUW7M1 (Ticlopidine); R16CO5Y76E (Aspirin)
[Em] Mês de entrada:1708
[Cu] Atualização por classe:170814
[Lr] Data última revisão:
170814
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170329
[St] Status:MEDLINE


  10 / 7328 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28293274
[Au] Autor:Ocneanu AF; deKemp RA; Renaud JM; Adler A; Beanlands RS; Klein R
[Ad] Endereço:Systems and Computer Engineering, Carleton University, Ottawa, ON, Canada.
[Ti] Título:Optimally Repeatable Kinetic Model Variant for Myocardial Blood Flow Measurements with Rb PET.
[So] Source:Comput Math Methods Med;2017:6810626, 2017.
[Is] ISSN:1748-6718
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Myocardial blood flow (MBF) quantification with Rb positron emission tomography (PET) is gaining clinical adoption, but improvements in precision are desired. This study aims to identify analysis variants producing the most repeatable MBF measures. 12 volunteers underwent same-day test-retest rest and dipyridamole stress imaging with dynamic Rb PET, from which MBF was quantified using 1-tissue-compartment kinetic model variants: (1) blood-pool versus uptake region sampled input function (Blood/Uptake-ROI), (2) dual spillover correction (SOC-On/Off), (3) right blood correction (RBC-On/Off), (4) arterial blood transit delay (Delay-On/Off), and (5) distribution volume (DV) constraint (Global/Regional-DV). Repeatability of MBF, stress/rest myocardial flow reserve (MFR), and stress/rest MBF difference (ΔMBF) was assessed using nonparametric reproducibility coefficients (RPC = 1.45 × interquartile range). MBF using SOC-On, RVBC-Off, Blood-ROI, Global-DV, and Delay-Off was most repeatable for combined rest and stress: RPC = 0.21 mL/min/g (15.8%). Corresponding MFR and ΔMBF RPC were 0.42 (20.2%) and 0.24 mL/min/g (23.5%). MBF repeatability improved with SOC-On at stress ( < 0.001) and tended to improve with RBC-Off at both rest and stress ( < 0.08). DV and ROI did not significantly influence repeatability. The Delay-On model was overdetermined and did not reliably converge. MBF and MFR test-retest repeatability were the best with dual spillover correction, left atrium blood input function, and global DV.
[Mh] Termos MeSH primário: Processamento de Imagem Assistida por Computador/métodos
Tomografia por Emissão de Pósitrons
Rubídio/química
[Mh] Termos MeSH secundário: Adulto
Idoso
Idoso de 80 Anos ou mais
Algoritmos
Estudos de Coortes
Doença da Artéria Coronariana/diagnóstico por imagem
Doença da Artéria Coronariana/fisiopatologia
Circulação Coronária
Dipiridamol/química
Feminino
Hemodinâmica
Seres Humanos
Cinética
Masculino
Meia-Idade
Imagem de Perfusão do Miocárdio
Radioisótopos
Reprodutibilidade dos Testes
Tomografia Computadorizada por Raios X
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Radioisotopes); 64ALC7F90C (Dipyridamole); MLT4718TJW (Rubidium)
[Em] Mês de entrada:1704
[Cu] Atualização por classe:170403
[Lr] Data última revisão:
170403
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170316
[St] Status:MEDLINE
[do] DOI:10.1155/2017/6810626



página 1 de 733 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde